Semaglutide# Semaglutide is a 31-amino acid GLP-1 analog with Aib substitution at position 8 (DPP-4 resistance) and C18 fatty diacid at Lys26 (albumin binding, ~7-day half-life)
By including all English-language studies on muscle mass loss during GLP-1RA therapy in T2D and obesity from major scientific databases and clinical trial registries, this narrative review synthesizes the current knowledge on the epidemiology and mechanisms of muscle loss in diabetes and obesity, with a focus on the impact of GLP-1RAs therapy
If you notice this pattern, consider timing pasta consumption for days when you feel least affected by the medication
In a recent episode of The Ultimate Human Podcast, host and human biologist Gary Brecka interviewed pharmaceutical expert and clinical researcher Dr
These questions have puzzled researchers for decades
The FDA last week issued warning letters against a handful of companies flagging violations regarding the promotion and sale of unapproved weight-loss drugs, including unlicensed versions of the blockbuster therapies semaglutide and tirzepatide